Retrieve available abstracts of 63 articles: HTML format
Single Articles
April 2025
HUGHES DJ, Chand G, Johnson J, Tegala R, et al PD-L1 imaging with [(99m)Tc]NM-01 SPECT/CT is associated with metabolic response
to pembrolizumab with/without chemotherapy in advanced lung cancer.
Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02991. PubMedAbstract available
COLANGELO T, Mazzarelli F, Cuttano R, Dama E, et al Unveiling the origin and functions of diagnostic circulating microRNAs in lung
cancer.
Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02982. PubMedAbstract available
WANG M, Kim RY, Kohonen-Corish MRJ, Chen H, et al Particulate matter air pollution as a cause of lung cancer: epidemiological and
experimental evidence.
Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02999. PubMedAbstract available
LIN X, Liu Z, Zhou K, Li Y, et al Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and
dynamically predicting immunotherapy response in NSCLC.
Br J Cancer. 2025;132:558-568. PubMedAbstract available
ZHANG W, Wang J, Liang J, He Z, et al RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant
NSCLC.
Br J Cancer. 2025;132:569-579. PubMedAbstract available
HONG CT, Yang YE, Juan HF, Chang CP, et al GDP-bound Rab37 modulates M2-like tumor-associated macrophage polarization by
attenuating STAT1 translocation to downregulate the type I IFN pathway.
Br J Cancer. 2025;132:622-634. PubMedAbstract available
January 2025
WALLS GM, Bergom C, Mitchell JD, Rentschler SL, et al Correction: Cardiotoxicity following thoracic radiotherapy for lung cancer.
Br J Cancer. 2025 Jan 7. doi: 10.1038/s41416-024-02926. PubMed
December 2024
CUTTY SJ, Hughes FA, Ortega-Prieto P, Desai S, et al Pro-survival roles for p21(Cip1/Waf1) in non-small cell lung cancer.
Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02928. PubMedAbstract available
LIU C, Reger M, Fan H, Wang J, et al Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the
prostate, lung, colorectal, and ovarian cancer screening trial.
Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929. PubMedAbstract available
POPAT S, Januszewski A, O'Brien M, Ahmad T, et al Long term efficacy of first-line afatinib and the clinical utility of ctDNA
monitoring in patients with suspected or confirmed EGFR mutant non-small cell
lung cancer who were unsuitable for chemotherapy.
Br J Cancer. 2024 Dec 5. doi: 10.1038/s41416-024-02901. PubMedAbstract available
November 2024
NORONHA V, Menon N, Patil VM, Shah M, et al Pregabalin for chronic cough due to lung cancer: randomized, double-blind,
placebo-controlled trial.
Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02913. PubMedAbstract available
POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892. PubMedAbstract available
WALLS GM, Bergom C, Mitchell JD, Rentschler SL, et al Cardiotoxicity following thoracic radiotherapy for lung cancer.
Br J Cancer. 2024 Nov 6. doi: 10.1038/s41416-024-02888. PubMedAbstract available
HEKTOEN HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, et al Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide
cohort study.
Br J Cancer. 2024 Nov 3. doi: 10.1038/s41416-024-02895. PubMedAbstract available
WEI J, Zhou S, Chen G, Chen T, et al GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its
molecular mechanism in malignant progression.
Br J Cancer. 2024;131:1529-1542. PubMedAbstract available
CHANDOURI B, Naves T, Yassine M, Ikhlef L, et al Comparison of methods for cancer stem cell detection in prognosis of early stages
NSCLC.
Br J Cancer. 2024;131:1425-1436. PubMedAbstract available
LIU X, Min Q, Cheng X, Zhang W, et al Quiescent cancer cells induced by high-density cultivation reveals
cholesterol-mediated survival and lung metastatic traits.
Br J Cancer. 2024;131:1591-1604. PubMedAbstract available
October 2024
WANG Y, Ju X, Hua R, Chen J, et al Deep learning analysis of histopathological images predicts immunotherapy
prognosis and reveals tumour microenvironment features in non-small cell lung
cancer.
Br J Cancer. 2024 Oct 25. doi: 10.1038/s41416-024-02856. PubMedAbstract available
MANDAL T, Shukla D, Khan MMA, Ganesan SK, et al The EXO1/Poleta/Poliota axis as a promising target for miR-3163-mediated attenuation
of cancer stem-like cells in non-small cell lung carcinoma.
Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02840. PubMedAbstract available
August 2024
MIGLIETTA G, Russo M, Capranico G, Marinello J, et al Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell
lung cancer: a feasible strategy?
Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02821. PubMedAbstract available
ABDIPOURBOZORGBAGHI M, Vancura A, Radpour R, Haefliger S, et al Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and
potential predictive biomarkers in non-small cell lung cancer (NSCLC).
Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02831. PubMedAbstract available
ROGERS I, Cooper M, Memon A, Forbes L, et al The effect of comorbidities on diagnostic interval for lung cancer in England: a
cohort study using electronic health record data.
Br J Cancer. 2024 Aug 23. doi: 10.1038/s41416-024-02824. PubMedAbstract available
NAGELBERG AL, Sihota TS, Chuang YC, Shi R, et al Integrative genomics identifies SHPRH as a tumor suppressor gene in lung
adenocarcinoma that regulates DNA damage response.
Br J Cancer. 2024;131:534-550. PubMedAbstract available
BUDCZIES J, Romanovsky E, Kirchner M, Neumann O, et al KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung
adenocarcinoma.
Br J Cancer. 2024;131:524-533. PubMedAbstract available
July 2024
JEONG H, Koh J, Kim S, Song SG, et al Correction: Epithelial-mesenchymal transition induced by tumor cell-intrinsic
PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in
PD-L1-high lung cancer.
Br J Cancer. 2024 Jul 30. doi: 10.1038/s41416-024-02798. PubMed
June 2024
ZHAO Y, Zheng Y, Fu J, Zhang J, et al KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient
non-small cell lung cancer.
Br J Cancer. 2024 Jun 29. doi: 10.1038/s41416-024-02772. PubMedAbstract available
GULIKERS JL, Otten LS, Hendriks LEL, Winckers K, et al Proactive monitoring of drug-drug interactions between direct oral anticoagulants
and small-molecule inhibitors in patients with non-small cell lung cancer.
Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02744. PubMedAbstract available
KATO T, Yang JC, Ahn MJ, Sakai H, et al Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET
exon 14 skipping enrolled in VISION.
Br J Cancer. 2024;130:1679-1686. PubMedAbstract available
May 2024
YOSHIMURA A, Horinaka M, Yaoi T, Ono H, et al Epithelial-mesenchymal transition status is a remarkable biomarker for the
combination treatment with avutometinib and defactinib in KRAS-mutated non-small
cell lung cancer.
Br J Cancer. 2024 May 31. doi: 10.1038/s41416-024-02727. PubMedAbstract available
MALAPELLE U, Leighl N, Addeo A, Hershkovitz D, et al Recommendations for reporting tissue and circulating tumour (ct)DNA
next-generation sequencing results in non-small cell lung cancer.
Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02709. PubMedAbstract available
JEONG H, Koh J, Kim S, Song SG, et al Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling
predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung
cancer.
Br J Cancer. 2024 May 10. doi: 10.1038/s41416-024-02698. PubMedAbstract available
April 2024
LI C, Liu L, You R, Li Y, et al Trajectory patterns and cumulative burden of CEA during follow-up with non-small
cell lung cancer outcomes: A retrospective longitudinal cohort study.
Br J Cancer. 2024 Apr 9. doi: 10.1038/s41416-024-02678. PubMedAbstract available
MATHIESON L, Koppensteiner L, Dorward DA, O'Connor RA, et al Cancer-associated fibroblasts expressing fibroblast activation protein and
podoplanin in non-small cell lung cancer predict poor clinical outcome.
Br J Cancer. 2024 Apr 6. doi: 10.1038/s41416-024-02671. PubMedAbstract available
BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al Farnesyl-transferase inhibitors show synergistic anticancer effects in
combination with novel KRAS-G12C inhibitors.
Br J Cancer. 2024;130:1059-1072. PubMedAbstract available
GORGULHO J, Roderburg C, Beier F, Bokemeyer C, et al Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as
predictive biomarkers in patients undergoing immune checkpoint blockade for solid
malignancies.
Br J Cancer. 2024;130:1013-1022. PubMedAbstract available
KANAHORI M, Shimada E, Matsumoto Y, Endo M, et al Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM
inhibits CD8(+) T cell infiltration.
Br J Cancer. 2024;130:1083-1095. PubMedAbstract available
March 2024
HARATANI K, Nakamura A, Mamesaya N, Sawa K, et al Association of immune-related adverse events with durvalumab efficacy after
chemoradiotherapy in patients with unresectable Stage III non-small cell lung
cancer.
Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662. PubMedAbstract available
FU X, Liu S, Cao D, Li C, et al Med23 deficiency reprograms the tumor microenvironment to promote lung
tumorigenesis.
Br J Cancer. 2024;130:716-727. PubMedAbstract available
BLANCO E, Silva-Pilipich N, Bocanegra A, Chocarro L, et al Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise
tumours to PD-1/PD-L1 blockade strategies.
Br J Cancer. 2024;130:869-879. PubMedAbstract available
February 2024
BLECHTER B, Wong JYY, Chien LH, Shiraishi K, et al Age at lung cancer diagnosis in females versus males who never smoke by race and
ethnicity.
Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02592. PubMedAbstract available
SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al Correction: Targeting serine/glycine metabolism improves radiotherapy response in
non-small cell lung cancer.
Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02603. PubMed
FONT A, Mellado B, Climent MA, Virizuela JA, et al Phase II trial of afatinib in patients with advanced urothelial carcinoma with
genetic alterations in ERBB1-3 (LUX-Bladder 1).
Br J Cancer. 2024;130:434-441. PubMedAbstract available
January 2024
REN Z, Dharmaratne M, Liang H, Benard O, et al Redox signalling regulates breast cancer metastasis via phenotypic and metabolic
reprogramming due to p63 activation by HIF1alpha.
Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02522. PubMedAbstract available
MEZQUITA L, Oulhen M, Aberlenc A, Deloger M, et al Resistance to BRAF inhibition explored through single circulating tumour cell
molecular profiling in BRAF-mutant non-small-cell lung cancer.
Br J Cancer. 2024 Jan 4. doi: 10.1038/s41416-023-02535. PubMedAbstract available
LEONETTI A, Verze M, Minari R, Perrone F, et al Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of
molecular genotyping on tissue and liquid biopsies.
Br J Cancer. 2024;130:135-142. PubMedAbstract available
December 2023
SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al Targeting serine/glycine metabolism improves radiotherapy response in non-small
cell lung cancer.
Br J Cancer. 2023 Dec 30. doi: 10.1038/s41416-023-02553. PubMedAbstract available
CHEN B, Yao W, Li X, Lin G, et al A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus
anlotinib as first-line treatment in patients with advanced non-small cell lung
cancer.
Br J Cancer. 2023 Dec 18. doi: 10.1038/s41416-023-02519. PubMedAbstract available
POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung
cancer: the Phase 2 randomized PIPSeN trial.
Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514. PubMedAbstract available
THOMPSON JC, Scholes DG, Carpenter EL, Aggarwal C, et al Molecular response assessment using circulating tumor DNA (ctDNA) in advanced
solid tumors.
Br J Cancer. 2023;129:1893-1902. PubMedAbstract available
November 2023
ESLAMI-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, et al Circulating tumour cells and PD-L1-positive small extracellular vesicles: the
liquid biopsy combination for prognostic information in patients with metastatic
non-small cell lung cancer.
Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02491. PubMedAbstract available
QU FJ, Zhou Y, Wu S Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer
with liver metastases.
Br J Cancer. 2023 Nov 9. doi: 10.1038/s41416-023-02482. PubMedAbstract available
HUNTER B, Argyros C, Inglese M, Linton-Reid K, et al Radiomics-based decision support tool assists radiologists in small lung nodule
classification and improves lung cancer early diagnosis.
Br J Cancer. 2023 Nov 6. doi: 10.1038/s41416-023-02480. PubMedAbstract available
SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al Correction: Tumor microenvironment-mediated immune profiles and efficacy of
anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell
lung cancer.
Br J Cancer. 2023 Nov 3. doi: 10.1038/s41416-023-02481. PubMed
TANG M, Burgess JT, Fisher M, Boucher D, et al Targeting the COMMD4-H2B protein complex in lung cancer.
Br J Cancer. 2023 Nov 1. doi: 10.1038/s41416-023-02476. PubMedAbstract available
SHEN M, Liu S, Toland A, Hsu EC, et al ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
Br J Cancer. 2023;129:1818-1828. PubMedAbstract available
October 2023
JANI BD, Sullivan MK, Hanlon P, Nicholl BI, et al Personalised lung cancer risk stratification and lung cancer screening: do
general practice electronic medical records have a role?
Br J Cancer. 2023 Oct 25. doi: 10.1038/s41416-023-02467. PubMedAbstract available
YANG Z, Zhu J, Yang T, Tang W, et al Comprehensive analysis of the lncRNAs-related immune gene signatures and their
correlation with immunotherapy in lung adenocarcinoma.
Br J Cancer. 2023;129:1397-1408. PubMedAbstract available
SICARD G, Protzenko D, Giacometti S, Barlesi F, et al Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing
lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.
Br J Cancer. 2023;129:1373-1382. PubMedAbstract available
PARRA ER, Ilie M, Wistuba II, Hofman P, et al Quantitative multiplexed imaging technologies for single-cell analysis to assess
predictive markers for immunotherapy in thoracic immuno-oncology: promises and
challenges.
Br J Cancer. 2023;129:1417-1431. PubMedAbstract available
September 2023
SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1
antibody plus chemotherapy stratified by DLL3 expression in small-cell lung
cancer.
Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02427. PubMedAbstract available
GASSLER N, Zhang C, Wenger T, Schnabel PA, et al Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung
carcinoma samples treated ex vivo.
Br J Cancer. 2023 Sep 18. doi: 10.1038/s41416-023-02433. PubMed
LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al Exposure to low-level ambient air pollution and the relationship with lung and
bladder cancer in older men, in Perth, Western Australia.
Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411. PubMedAbstract available
YANG Y, Xu S, Jia G, Yuan F, et al Integrating genomics and proteomics data to identify candidate plasma biomarkers
for lung cancer risk among European descendants.
Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419. PubMedAbstract available